Title : The Androgen-Regulated Protease TMPRSS 2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis

Running Title: TMPRSS2 Influences Prostate Cancer Metastasis

[1]  M. Rubin,et al.  Aggressive Variants of Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.

[2]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[3]  G. Shapiro,et al.  Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Gutkind,et al.  c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase , 2010, Oncogene.

[5]  S. Horvath,et al.  Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance , 2010, Nature Medicine.

[6]  Jie Zhang,et al.  Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie Specific Translocations in Cancer , 2009, Cell.

[7]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[8]  T. Bugge,et al.  Type II Transmembrane Serine Proteases* , 2009, The Journal of Biological Chemistry.

[9]  Hui Wang,et al.  CXCR4 and SDF-1 Production Are Stimulated by Hepatocyte Growth Factor and Promote Glioma Cell Invasion , 2009, Oncology Research and Treatment.

[10]  Madhuchhanda Bhattacharjee,et al.  Conserved gene expression programs integrate mammalian prostate development and tumorigenesis. , 2009, Cancer research.

[11]  J. Massagué,et al.  Molecular basis of metastasis. , 2008, The New England journal of medicine.

[12]  R. Weinberg.  Leaving home early: reexamination of the canonical models of tumor progression. , 2008, Cancer cell.

[13]  J. Chevillet,et al.  Identification and characterization of small-molecule inhibitors of hepsin , 2008, Molecular Cancer Therapeutics.

[14]  T. Golub,et al.  Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. , 2008, Journal of the National Cancer Institute.

[15]  T. Bugge,et al.  Type II transmembrane serine proteases in development and disease. , 2008, The international journal of biochemistry & cell biology.

[16]  M. Matsumura,et al.  The androgen‐regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma , 2008, The Journal of pathology.

[17]  K. Pienta,et al.  A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. , 2007, Molecular cell.

[18]  G. Christofori,et al.  Hepatocyte growth factor induces cell scattering through MAPK/Egr‐1‐mediated upregulation of Snail , 2006, The EMBO journal.

[19]  P. Comoglio,et al.  Invasive growth: a MET-driven genetic programme for cancer and stem cells , 2006, Nature Reviews Cancer.

[20]  Francesco Leonetti,et al.  Substrate Profiling of Cysteine Proteases Using a Combinatorial Peptide Library Identifies Functionally Unique Specificities* , 2006, Journal of Biological Chemistry.

[21]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[22]  V. Adhami,et al.  A Novel Biomarker for Staging Human Prostate Adenocarcinoma: Overexpression of Matriptase with Concomitant Loss of its Inhibitor, Hepatocyte Growth Factor Activator Inhibitor-1 , 2006, Cancer Epidemiology Biomarkers & Prevention.

[23]  P. Nelson,et al.  Phenotypic Analysis of Mice Lacking the Tmprss2-Encoded Protease , 2006, Molecular and Cellular Biology.

[24]  C. Craik,et al.  Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. , 2005, The Biochemical journal.

[25]  G. Woude,et al.  Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor , 2005, Oncogene.

[26]  Aaron Shipway,et al.  Biochemical characterization of prostasin, a channel activating protease. , 2004, Biochemical and biophysical research communications.

[27]  O. Klezovitch,et al.  Hepsin promotes prostate cancer progression and metastasis. , 2004, Cancer cell.

[28]  T. Ratliff.  Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report From the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee , 2004 .

[29]  Robert D Cardiff,et al.  Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. , 2004, Cancer research.

[30]  E. Davie,et al.  A Brief Historical Review of the Waterfall/Cascade of Blood Coagulation , 2003, Journal of Biological Chemistry.

[31]  James P. Quigley,et al.  Membrane anchored serine proteases: A rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer , 2003, Cancer and Metastasis Reviews.

[32]  R. Vessella,et al.  LuCaP 35: A new model of prostate cancer progression to androgen independence , 2003, The Prostate.

[33]  Tsuey-Ming Chen,et al.  Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model , 2003, The Prostate.

[34]  Douglas S Scherr,et al.  High expression of the Met receptor in prostate cancer metastasis to bone. , 2002, Urology.

[35]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[36]  Jeffrey A. Magee,et al.  Expression profiling reveals hepsin overexpression in prostate cancer. , 2001, Cancer research.

[37]  G. V. Vande Woude,et al.  Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. , 2001, The American journal of pathology.

[38]  J. Clements,et al.  Type II Transmembrane Serine Proteases , 2001, The Journal of Biological Chemistry.

[39]  C. Craik,et al.  Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Francesco Leonetti,et al.  Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin , 2000, Nature Biotechnology.

[41]  L. Hood,et al.  Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. , 1999, Cancer research.

[42]  K. Matsumoto,et al.  Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. , 1999, Critical reviews in oncology/hematology.

[43]  A. Hekman,et al.  Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+). , 1998, Experimental hematology.

[44]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.

[46]  H. Lilja,et al.  Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. , 1989, The Journal of biological chemistry.

[47]  J. Kondo,et al.  A novel protease obtained from FBS-containing culture supernatant, that processes single chain form hepatocyte growth factor to two chain form in serum-free culture , 2006, Cytotechnology.

[48]  T. Bugge,et al.  Matriptase: Potent Proteolysis on the Cell Surface , 2006, Molecular medicine.

[49]  M. Matsumura,et al.  Substrates of the prostate‐specific serine protease prostase/KLK4 defined by positional‐scanning peptide libraries , 2005, The Prostate.